shutterstock_383559112 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Karuna’s Phase II schizophrenia trial prompts expert caution

Eli Lilly’s xanomeline had previously been researched in Alzheimer’s disease and schizophrenia by independent researchers and was found to significantly improve behavioural symptoms.